Robert J. Kreitman

National Institutes of Health — United States

Immunology and Microbiology · Life Sciences

70h-index17.0kcitations346works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Toxin Mechanisms and Immunotoxins(187), Chronic Lymphocytic Leukemia Research(136), Transgenic Plants and Applications(106), Monoclonal and Polyclonal Antibodies Research(91), Lymphoma Diagnosis and Treatment(62)

Publications346 total

Phase 2 trial of cladribine plus immediate rituximab for 1st-line treatment of hairy cell leukemia – long term follow-up of original and additional patient cohorts
Blood·2025Open Access
MAP2K1 and MAP2K2 genes alterations in hairy cell leukemia and hairy cell leukemia variant.
Blood·2025Open Access
Phase 2 trial of encorafenib plus binimetinib for patients with BRAF V600 mutated relapsed/refractory hairy cell leukemia
Blood·2025Open Access
Expert consensus opinion on the management of hairy cell leukemia in elderly patients
Leukemia & lymphoma/Leukemia and lymphoma·2025
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia
Blood·2025· 1 citedOpen Access
Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell Therapy
JCO Precision Oncology·2025Open Access
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia
Leukemia·2025Open Access
194 | A NOVEL APPROACH FOR CLASSIFICATION OF SPLENIC B CELL LYMPHOMA USING DNA METHYLATION REVEALS DIVERSE BIOLOGICAL DISEASE MECHANISMS
Hematological Oncology·2025Open Access
A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia
Blood·2024Open Access
Non-V600E BRAF Gene Alterations in Hairy Cell Leukemia
Blood·2024· 1 citedOpen Access
COVID-19 vaccination in patients with classic and variant hairy cell leukemia
Blood Neoplasia·2024Open Access
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms
Leukemia·2024· 13 citedOpen Access
Effect of rituximab on remissions without minimal residual disease and immunogenicity in patients with relapsed/refractory hairy cell leukemia receiving moxetumomab pasudotox.
Journal of Clinical Oncology·2024· 1 cited
DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma
Blood·2023· 2 citedOpen Access
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
EClinicalMedicine·2023· 16 citedOpen Access
Characterization of B‐cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS‐CoV‐2 infection
Journal of Medical Virology·2023Open Access
COVID-19 in patients with classic and variant hairy cell leukemia
Blood Advances·2023· 5 citedOpen Access
Characterization of B-cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS-CoV-2 infection
2023Open Access
S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.
HemaSphere·2023Open Access
P606: MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL
HemaSphere·2023Open Access
page 1 of 18Next →

Frequent Co-authors

Ira Pastan(35), Raffit Hassan(10), Maryalice Stetler‐Stevenson(10), David J. FitzGerald(9), Wyndham H. Wilson(7), Masanori Onda(6), Byung Kook Lee(5), Evgeny Arons(4), Inger Margulies(4), Alan S. Wayne(4), Richard Beers(4), Vivek Subbiah(3), Zev A. Wainberg(3), Jan H.M. Schellens(3), Patrick Y. Wen(3), David Fitzgerald(3), Tadeusz Robak(3), Seth M. Steinberg(3), Raj K. Puri(3), Laiman Xiang(3)